ERAS

ERAS

USD

Erasca Inc. Common Stock

$1.520-0.060 (-3.797%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.580

Hoch

$1.615

Tief

$1.515

Volumen

1.46M

Unternehmensfundamentaldaten

Marktkapitalisierung

430.6M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.73M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $1.01Aktuell $1.520Hoch $3.45

Ähnliche Nachrichten

Analyst Upgrades

Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5

Raymond James analyst Laura Prendergast initiates coverage on Erasca with a Outperform rating and announces Price Target of $5.

Mehr anzeigen
Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5
GlobeNewswire

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors,

Mehr anzeigen
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Analyst Upgrades

Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3

Goldman Sachs analyst Chris Shibutani maintains Erasca with a Buy and lowers the price target from $3.5 to $3.

Mehr anzeigen
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca with a Buy and maintains $6 price target.

Mehr anzeigen
HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target
Analyst Upgrades

Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4

Morgan Stanley analyst Jeffrey Hung assumes Erasca with a Overweight rating and maintains Price Target of $4.

Mehr anzeigen
Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4